Alzheimer’s Disease-Eisai (Mission AD2)
This study is a Phase 3 clinical trial investigating the efficacy of preventing the progression and symptoms associated with Early Alzheimer’s Disease (EAD), including mild cognitive impairment (MCI) due to Alzheimer’s disease.
Sponsor: Eisai Inc
Indication: Mild cognitive impairment due to Alzheimer’s disease (AD) or mild AD dementia
Age: 50 to 85 years of age
Category: Disease Modifying
For more information: https://clinicaltrials.gov/ct2/show/NCT02956486